Astellas Pharma (4503) Q2 2027 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2027 earnings summary
11 Nov, 2026Executive summary
H1 revenue rose 23.4% YoY to ¥1,270.9bn; core operating profit increased 50.3% to ¥424.9bn, supported by Strategic Brands, cost discipline and favorable FX.
FY2026 guidance was raised; pipeline advances included two Phase 3 first-subject-dosed milestones, ASP6958 proof of concept in mCRPC and three new clinical-stage programs.
Financial highlights
Reported operating profit was ¥316.6bn, up 58.8% YoY; profit was ¥241.5bn, up 63.6%.
Core profit increased 56.8% to ¥331.5bn; basic core EPS rose 56.7% to ¥185.02.
Gross profit increased 23.3% to ¥1,023.0bn; SG&A rose 6.6% to ¥430.4bn and R&D expenses rose 17.0% to ¥167.7bn.
Strategic Brands sales reached ¥333.9bn, up 51.4%; XTANDI sales were ¥533.7bn, up 11.9%, with favorable FX contributing.
ASP5541 development was discontinued, resulting in a ¥26.4bn impairment loss.
Outlook and guidance
FY2026 revenue forecast rose ¥110bn to ¥2,330bn; core operating profit guidance increased ¥80bn to ¥700bn, targeting a 30.0% margin.
Full-basis operating profit forecast increased ¥65bn to ¥460bn; profit before tax is forecast at ¥450bn and profit at ¥350bn.
Core profit guidance rose ¥60bn to ¥520bn; basic core EPS forecast is ¥290.04.
Strategic Brands sales guidance increased to ¥680bn; XTANDI is expected to decline in 2H due to the US IRA impact, while PADCEV outlook increased.
Forecast FX assumptions are ¥158/US$ and ¥181/€; Q3 onward assumptions are ¥156/US$ and ¥177/€.
Latest events from Astellas Pharma
- Raised FY2026 outlook supports a pivot to pipeline-led growth from FY2029.4503
Investor presentation - FY26 margin target pulled forward as pipeline-led growth builds beyond XTANDI.4503
Jefferies Global Healthcare Conference - Sustainability efforts and governance reforms are driving measurable enterprise value and innovation.4503
Sustainable Meeting 2024 - Record revenue and profit growth led by strategic brands, pipeline advances, and global expansion.4503
Q1 2027 - Pipeline-led growth, high-margin brands, and oncology innovation to drive record revenues.4503
Jefferies Global Healthcare Conference 2026 - Record revenue and profit growth driven by Strategic Brands and cost optimization, with strong FY2026 outlook.4503
Q4 2026 - Double-digit revenue and profit growth led to upward guidance, driven by strategic brands.4503
Q3 2026 - Core operating profit surged 54.4% on 10.1% revenue growth and strong brand sales.4503
Q2 2026 - Q1 revenue up 26.2% year-on-year, driven by XTANDI and strategic brands, with strong profit growth.4503
Q1 2025